GI Dynamics Inc.
Latest From GI Dynamics Inc.
Results Recap: EndoBarrier Improves Obesity And Diabetes Outcomes In UK Study; Procept’s Aquablation Proves Effective Again
Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition covers new clinical data released March 8 to March 22, not including the data presented at the annual conferences of the American Academy of Orthopedic Surgeons or American College of Cardiology, which are presented in separate special editions of Results Recap.
Starts & Stops: Check-Cap Starts US Trial; Venous Valve Study Begins; CorMatrix Looks At ‘Living’ Tricuspid Valve
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Feb. 11 through Feb. 24, including announcements from CorMatrix Cardiovascular, Hancock Jaffe Laboratories, Toray Industries, Spectral Medical, GI Dynamics, and Check-Cap.
The global market for minimally invasive weight loss devices is expected to grow to $290m by 2021, a CAGR of 16%, driven in large part by the rising obesity epidemic and associated Type 2 diabetes. Meddevicetracker expects that enhancements and innovations, particularly in the growing intragastric balloon market, and emerging technologies by smaller companies, will lead the growth in the overall weight loss devices market. In this feature, we'll take a closer look at the overall market and regional landscape and take a deep dive into the fastest-growing intragastric balloon segment, providing key insights from a bariatric surgeon on the pros and cons of these technologies.
The final five-year results from the STAMPEDE trial, said to be the first randomized controlled trial in the bariatric space, show that bariatric surgery plus intensive medical therapy is more effective than intensive medical therapy alone in combating hyperglycemia in obese patients with type 2 diabetes.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- GI Dynamics Inc.
- Senior Management
Scott Schorer, Pres. & CEO
Dave Bruce, Dir., Fin.
- Contact Info
GI Dynamics Inc.
Phone: (781) 357-3300
P.O. Box 51915 Boston, MA 02205
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.